| Jennifer J Peacock, DNP, APRN, NNP-BC | |
|
2818 W 12875 S, Riverton, UT 84065-6837 | |
| (801) 232-6595 | |
| Not Available |
| Full Name | Jennifer J Peacock |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist - Neonatal |
| Location | 2818 W 12875 S, Riverton, Utah |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336513704 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SN0000X | Clinical Nurse Specialist - Neonatal | 289188-4405 (Utah) | Primary |
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942325154 PECOS PAC ID: 1850209420 Enrollment ID: O20080610000303 |
News Archive
A "humanized" mouse model equipped with the immune system of a patient who needs an organ transplant beats current measures for identifying the best potential living donor, scientists report.
In her new unwavering memoir, Jim's Journey: The Story of a Young Man with Early On-set Alzheimer's (published by Trafford Publishing), debut author Gretchen L Dausey reveals the touching story of her husband's battle against Alzheimer's disease and her unwavering support despite the inevitable degeneration of his mind and body.
Italian researchers at the Catholic University of Sacred Heart in Rome found an important molecular mechanism responsible for low back pain and other acute vertebral problems like cervical axial pain, all due to aging and degeneration of the vertebral column.
ISTO Technologies, Inc., an orthobiologics company with a cell-based platform for cartilage regeneration, announced today the completion of patient enrollment in the Phase I clinical study for NuQu™, an injectable formulation of juvenile chondrocytes designed for the treatment of discogenic back pain. The study included 15 patients enrolled at two clinical sites. All patients enrolled in the trial suffered from persistent discogenic back pain and disability despite undergoing previous traditional conservative therapy.
High-dose influenza vaccine is 24 percent more effective than the standard-dose vaccine in protecting persons ages 65 and over against influenza illness and its complications, according to a Vanderbilt-led study published today in the New England Journal of Medicine.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer J Peacock, DNP, APRN, NNP-BC 100 N Mario Capecchi Dr, Salt Lake City, UT 84113-1103 Ph: (801) 662-4100 | Jennifer J Peacock, DNP, APRN, NNP-BC 2818 W 12875 S, Riverton, UT 84065-6837 Ph: (801) 232-6595 |
News Archive
A "humanized" mouse model equipped with the immune system of a patient who needs an organ transplant beats current measures for identifying the best potential living donor, scientists report.
In her new unwavering memoir, Jim's Journey: The Story of a Young Man with Early On-set Alzheimer's (published by Trafford Publishing), debut author Gretchen L Dausey reveals the touching story of her husband's battle against Alzheimer's disease and her unwavering support despite the inevitable degeneration of his mind and body.
Italian researchers at the Catholic University of Sacred Heart in Rome found an important molecular mechanism responsible for low back pain and other acute vertebral problems like cervical axial pain, all due to aging and degeneration of the vertebral column.
ISTO Technologies, Inc., an orthobiologics company with a cell-based platform for cartilage regeneration, announced today the completion of patient enrollment in the Phase I clinical study for NuQu™, an injectable formulation of juvenile chondrocytes designed for the treatment of discogenic back pain. The study included 15 patients enrolled at two clinical sites. All patients enrolled in the trial suffered from persistent discogenic back pain and disability despite undergoing previous traditional conservative therapy.
High-dose influenza vaccine is 24 percent more effective than the standard-dose vaccine in protecting persons ages 65 and over against influenza illness and its complications, according to a Vanderbilt-led study published today in the New England Journal of Medicine.
› Verified 4 days ago